share_log

Hualan Biological Engineering Inc.'s (SZSE:002007) Top Owners Are Retail Investors With 38% Stake, While 29% Is Held by Private Companies

Hualan Biological Engineering Inc.'s (SZSE:002007) Top Owners Are Retail Investors With 38% Stake, While 29% Is Held by Private Companies

华兰生物工程有限公司”s (SZSE: 002007) 最大的股东是散户投资者,持有38%的股份,而29%的股份由私营公司持有
Simply Wall St ·  05/02 18:13

Key Insights

关键见解

  • Significant control over Hualan Biological Engineering by retail investors implies that the general public has more power to influence management and governance-related decisions
  • The top 5 shareholders own 51% of the company
  • 18% of Hualan Biological Engineering is held by insiders
  • 散户投资者对华兰生物工程的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
  • 前五名股东拥有公司51%的股份
  • 华兰生物工程 18% 的股份由内部人士持有

Every investor in Hualan Biological Engineering Inc. (SZSE:002007) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 38% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

华兰生物工程股份有限公司(深圳证券交易所:002007)的每位投资者都应该了解最强大的股东群体。持有该公司股份最多的集团是散户投资者,准确地说约为38%。也就是说,如果股票上涨,该集团将受益最大(如果出现低迷,则损失最大)。

Meanwhile, private companies make up 29% of the company's shareholders.

同时,私营公司占公司股东的29%。

In the chart below, we zoom in on the different ownership groups of Hualan Biological Engineering.

在下图中,我们放大了华兰生物工程的不同所有权群体。

ownership-breakdown
SZSE:002007 Ownership Breakdown May 2nd 2024
SZSE:002007 所有权明细 2024 年 5 月 2 日

What Does The Institutional Ownership Tell Us About Hualan Biological Engineering?

关于华兰生物工程,机构所有权告诉我们什么?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

许多机构根据近似于当地市场的指数来衡量自己的表现。因此,他们通常会更多地关注主要指数中包含的公司。

We can see that Hualan Biological Engineering does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Hualan Biological Engineering's earnings history below. Of course, the future is what really matters.

我们可以看到,华兰生物工程确实有机构投资者;他们持有该公司很大一部分股票。这意味着在这些机构工作的分析师已经看过这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看华兰生物工程的收益记录。当然,未来才是真正重要的。

earnings-and-revenue-growth
SZSE:002007 Earnings and Revenue Growth May 2nd 2024
SZSE: 002007 年收益和收入增长 2024 年 5 月 2 日

Hualan Biological Engineering is not owned by hedge funds. Our data shows that Kang An is the largest shareholder with 18% of shares outstanding. With 15% and 13% of the shares outstanding respectively, Chongqing Chengkang Biotechnology Development Co., Ltd. and Hong Kong Kekang Co., Ltd. are the second and third largest shareholders.

华兰生物工程不归对冲基金所有。我们的数据显示,康安是最大股东,已发行股份的18%。重庆诚康生物技术开发有限公司和香港科康股份有限公司分别拥有15%和13%的已发行股份,是第二和第三大股东。

Our research also brought to light the fact that roughly 51% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.

我们的研究还揭示了这样一个事实,即该公司约有51%的股份由前五名股东控制,这表明这些所有者对业务具有重大影响。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。有不少分析师报道了该股,因此你可以很容易地研究预测的增长。

Insider Ownership Of Hualan Biological Engineering

华兰生物工程的内部所有权

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

尽管内部人士的确切定义可能是主观的,但几乎每个人都认为董事会成员是内部人士。公司管理层经营业务,但首席执行官将对董事会负责,即使他或她是董事会成员。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。

It seems insiders own a significant proportion of Hualan Biological Engineering Inc.. It is very interesting to see that insiders have a meaningful CN¥6.5b stake in this CN¥36b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

内部人士似乎拥有华兰生物工程公司的很大一部分股份。有趣的是,内部人士在这项360亿元的业务中拥有65亿元人民币的大量股份。很高兴看到这样的投资水平。你可以在这里查看这些内部人士最近是否在买入。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 38% stake in Hualan Biological Engineering. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

公众通常是个人投资者,持有华兰生物工程38%的股份。尽管这个群体不一定能做主,但它肯定会对公司的运作方式产生真正的影响。

Private Company Ownership

私人公司所有权

We can see that Private Companies own 29%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我们可以看到,私人公司拥有29%的已发行股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过独立的私人公司持有上市公司的股份权益。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Hualan Biological Engineering better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Hualan Biological Engineering you should know about.

拥有公司股份的不同群体总是值得考虑的。但是,要更好地了解华兰生物工程,我们需要考虑许多其他因素。例如,考虑风险。每家公司都有它们,我们已经发现了一个你应该知道的华兰生物工程警告标志。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

归根结底,未来是最重要的。您可以访问这份关于公司分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发